

**Table 8. Adult parenteral antimicrobial dosage guidelines**

Antibiotic	Usual Dosages*
<b>ANTIBACTERIAL AGENTS</b>	
<i>Penicillins</i>	
ampicillin	1-2 g q4-6h
cloxacillin	2 g q4-6h
penicillin G	2-4 million units q4-6h
piperacillin-tazobactam	3.375 g q6h
meropenem	500 mg q6h
<i>Cephalosporins</i>	
cefazolin	1-2 g q8h
cefoxitin	1-2 g q6-8h
cefuroxime	0.75-1.5 g q8h
ceftriaxone	1-2 g q24h
ceftazidime	1-2 g q8h
<i>Fluoroquinolones</i>	
ciprofloxacin	400 mg q12h
levofloxacin	500-750 mg q24h
moxifloxacin	400 mg q24h
<i>Macrolides</i>	
azithromycin	500 mg q24h
<i>Aminoglycosides</i>	
gentamicin or tobramycin	80 mg q8h
<i>Others</i>	
clindamycin	600 mg q8h
cotrimoxazole (TMP-SMX)	10-20 mg/kg/day trimethoprim in divided doses q6-8h
metronidazole	500 mg q8h
vancomycin	1 g q12h or 15 mg/kg q12h
<b>ANTIFUNGAL AGENTS</b>	
amphotericin B	0.5-1 mg/kg q24h
fluconazole	100-400 mg q24h
casposfungin	70 mg load then 50 mg q24h
<b>ANTIVIRAL AGENTS</b>	
acyclovir	5-10 mg/kg/dose q8h
ganciclovir	5 mg/kg/dose q12h

\* Based on normal renal function in a 70 kg patient.

**Table 9. Parenteral to oral conversion suggestions**

Parenteral Drug	Oral Therapy Options*
<b>ANTIBACTERIAL AGENTS</b>	
<i>Penicillins</i>	
ampicillin	amoxicillin
cloxacillin	cloxacillin or cephalixin
penicillin G	penicillin V
piperacillin-tazobactam	amoxicillin-clavulanate or cotrimoxazole (TMP-SMX) +/- metronidazole or ciprofloxacin +/- metronidazole
<i>Cephalosporins</i>	
cefazolin	cephalexin or cloxacillin
cefoxitin	cephalexin + metronidazole or cotrimoxazole + metronidazole or amoxicillin-clavulanate
cefuroxime	cotrimoxazole or amoxicillin-clavulanate or azithromycin/clarithromycin
ceftriaxone	amoxicillin-clavulanate or cephalixin or ciprofloxacin/levofloxacin/moxifloxacin
ceftazidime	ciprofloxacin
<i>Fluoroquinolones</i>	
ciprofloxacin	ciprofloxacin
levofloxacin	levofloxacin
moxifloxacin	moxifloxacin
<i>Macrolides</i>	
azithromycin	azithromycin
<i>Others</i>	
clindamycin	cloxacillin +/- metronidazole or cephalixin +/- metronidazole or clindamycin
<b>ANTIFUNGAL AGENTS</b>	
fluconazole	fluconazole
<b>ANTIVIRAL AGENTS</b>	
acyclovir	acyclovir or valacyclovir

\* Patients should be clinically stable, demonstrate clinical improvement, and be able to tolerate oral feeding and medications. Selection of oral therapy should be based on cultures and sensitivities. In absence of useful cultures, oral therapy may be selected based on potential pathogens, community- versus hospital-acquired infection, pharmacokinetics, spectrum of activity, and cost of each oral agent. Oral agents listed above represent those currently on the WRHA Formulary and **does not** represent all commercially available oral agents.

**Table 10. Adult dosing recommendations in renal impairment\***

Drug	Creatinine Clearance (CrCl) in mL/min <sup>b</sup> (suggested dosage adjustment based on normal dose)			
<b>Penicillins</b>				
ampicillin	> 30 (q6h)	10-30 (q6-12h)	< 10 (q12h)	
cloxacillin	NO CHANGE NECESSARY			
penicillin	> 50 (q4-6h)	10-50 (q6-8h)	< 10 (20-50% of usual dose) <sup>a</sup>	
piperacillin (+ tazobactam)	> 40 (q6h)	20-40 (q8h)	< 20 (q12h)	
<b>Carbapenems</b>				
meropenem	> 50 (q6h)	30-49 (q8h)	10-29 (q12h)	< 10 (q24h)
<b>Cephalosporins</b>				
cefazolin	> 50 (q8h)	10-50 (q12h)	< 10 (q24h)	
cefoxitin	> 30 (q6-8h)	10-30 (q12-24h)	< 10 (q24h)	
cefuroxime	> 20 (q8h)	10-20 (q12h)	< 10 (q24h)	
ceftriaxone	NO CHANGE NECESSARY			
ceftazidime	> 50 (q8h)	30-50 (q12h)	10-30 (q24h)	< 10 (50% q24-48h)
<b>Aminoglycosides<sup>c</sup></b>				
gentamicin/ tobramycin/ amikacin	Contact the Pharmacist at your facility for dosing assistance			
<b>Fluoroquinolones</b>				
ciprofloxacin	> 30 (q12h)	< 30 (q24h)		
levofloxacin (e.g. CAP)	> 50 (q24h)	20-49 (500 mg load, then 50% q24h)	10-19 (500 mg load, then 50% q48h)	
moxifloxacin	NO CHANGE NECESSARY			
<b>Macrolides</b>				
azithromycin	NO CHANGE NECESSARY			
<b>Antifungal Agents</b>				
fluconazole	> 50 (q24h)	20-50 (50% q24h)	< 20 (25% of usual dose q24h)	
casposfungin	NO CHANGE NECESSARY			
<b>Antiviral Agents</b>				
acyclovir	> 50 (q8h)	25-50 (q12h)	10-25 (q24h)	< 10 (50% q24h)
ganciclovir (induction doses)	50-69 2.5 mg/kg q12h	25-49 2.5 mg/kg q24h	10-25 1.25 mg/kg q24h	< 10 1.25 mg/kg 3x/wk
<b>Miscellaneous</b>				
clindamycin	NO CHANGE NECESSARY			
metronidazole	NO CHANGE NECESSARY			
cotrimoxazole (TMP-SMX)	> 25 (q6-8h)	15-25 (50% q6-8h)	< 15 (2.5-5 mg/kg, generally not recommended) <sup>a</sup>	
vancomycin <sup>d</sup>	Contact the Pharmacist at your facility for dosing assistance			

\* Suggested dosages – for individualized dosage modifications or more information contact the Pharmacy Department at your facility.

<sup>b</sup> To estimate creatinine clearance (CL<sub>CR</sub>) (mL/min) use the following calculation normalized for a 72 kilogram person.

CL<sub>CR</sub> male =  $\frac{(140 - \text{age}) \times 88.4}{S_{Cr}}$  (µmoles/L)  
CL<sub>CR</sub> female = 0.85 x CL<sub>CR</sub> male

<sup>c</sup> Monitor serum concentrations.



## Seven Oaks General Hospital Antibiogram for 2021 (Based on data from 2020)

Provided by:  
Shared Health, Clinical Microbiology Discipline

For further information contact:

Andrew Walkty, MD, FRCPC  
Medical Microbiologist, Health Sciences Centre/Shared Health

or

Heather J. Adam, PhD, D(ABMM), FCCM  
Clinical Microbiologist, Health Sciences Centre/Shared Health

or

Philippe Lagacé-Wiens, MD, FRCPC  
Medical Microbiologist, St. Boniface Hospital/Shared Health

## DISCLAIMERS

This guide is provided as an educational resource for physicians and other healthcare professionals caring for patients at the Seven Oaks General Hospital. The authors of the guide have made every effort to ensure that the information contained in it was accurate at the time of publication. Users of the guide are encouraged to consult other references to confirm the information presented in it. The authors are not responsible for errors, omissions, inaccuracies, or the continued completeness of the information contained in the guide. The information in the guide should not be used or relied upon to replace the skill and professional judgment required to determine appropriate patient care and treatment. Also, the guide is not intended to replace or to be used as a substitute for the complete prescribing information prepared by each pharmaceutical manufacturer for their anti-infective agents. Because of possible changes in anti-infective indications, changes in dosage information, differences in patients' responses to therapy, newly described toxicities, drug-drug interactions, and other items of importance, reference to complete prescribing information is recommended before any of the anti-infective agents described in the guide are used.

## HOW TO USE THE ANTILOGRAM PORTION OF THE GUIDE (Tables 1-6)

- The information presented in the antibiogram is intended only to guide initial empiric anti-infective agent therapy at the Seven Oaks General Hospital.

- Initial broad-spectrum empiric therapy should be focused to the most appropriate narrow-spectrum agent(s) based on the laboratory identification of pathogen(s) and known susceptibility patterns/results, if the situation permits.

- Consideration should be given to equally efficacious but less expensive anti-infective agents for empiric therapy or when streamlining of therapy is desired, if the situation permits.

## SUGGESTED CRITERIA FOR IV TO ORAL ANTIBIOTIC CONVERSION IN ADULTS

- Clinical improvement of infectious signs and symptoms (e.g., temperature defervescence, decreased white blood cell count).

- Patient is clinically stable (excludes patients in the intensive care unit, patients with febrile neutropenia, or patients with life threatening infections).

- Patient can tolerate oral feeding and medications (bowel sounds, no diarrhea/nausea/vomiting).

- For rapid step-down, choose agents with high bioavailability (e.g., clindamycin, cotrimoxazole (TMP-SMX), fluoroquinolones).

- If anti-infective agent susceptibilities are known, anti-infective therapy should be tailored based on available data.

**Table 1. In vitro activity of selected anti-infective agents tested against Gram-negative bacilli<sup>a</sup>**

Organism (number tested): January through December 2020	Percent Susceptible														
	Ampicillin	Amoxicillin-Clavulanate	Piperacillin-Tazobactam	Ceftazidime	Cephalosporin <sup>b</sup>	Cefuroxime	Ceftazidime	Ceftazidime	Ertapenem	Meropenem	Gentamicin	Tobramycin	Ciprofloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin <sup>c</sup>
<i>Citrobacter</i> spp. (39)			85				72	72	100	100	85	92	64	74	92
<i>Enterobacter cloacae</i> complex (30)			80				60	70	83	100	90	83	77	77	47
<i>Escherichia coli</i> (38) systemic	45	84	95	47			84	84	97	97	89	87	63	58	
<i>Escherichia coli</i> (326) urine	51	83	96	60	n.d.		84	88	100	100	90	91	57	67	97
<i>Haemophilus influenzae</i> (75) <sup>d</sup>	65	n.d.				97								64	
<i>Klebsiella pneumoniae</i> (52)		92	100	79	n.d.		90	90	100	100	92	90	71	87	29
<i>Proteus mirabilis</i> (68)	84	99	100	n.d.	n.d.		99	99	100	100	96	96	91	82	
<i>Pseudomonas aeruginosa</i> (66)			92					92		95	98	100	83		

<sup>a</sup> Isolates tested and reported are from all sources combined, with the exception of *Escherichia coli* (subdivided into systemic isolates and urine isolates); isolates were collected from Jan 1 to Dec 31, 2020 with the exception of *Citrobacter* spp. and *Proteus mirabilis* (collected from Jan 2019 to Dec 2020); data compiled according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) in their document M39-A4 (2014).

<sup>b</sup> Cephalosporin is only indicated for the treatment of uncomplicated lower urinary tract infections.

<sup>c</sup> Nitrofurantoin is only indicated for acute cystitis.

<sup>d</sup> *H. influenzae* data obtained from isolates tested at Health Sciences Centre, Jan 1 to Dec 31, 2017. Sixty-one isolates were tested for Cefuroxime and 69 isolates were tested for Trimethoprim-Sulfamethoxazole.

n.d. = no data – absence of data for certain drug-organism combinations reflects limitations of the testing method currently used by Shared Health Clinical Microbiology laboratories.

**Table 2. In vitro activity of selected anti-infective agents tested against Gram-positive cocci<sup>a</sup>**

Organism (number tested): January through December 2020	Percent Susceptible														
	Penicillin	Ampicillin	Oxacillin <sup>b</sup>	Vancomycin	Daptomycin	High-Level Gentamicin	High-Level Streptomycin <sup>c</sup>	Erythromycin <sup>d</sup>	Clindamycin	Trimethoprim-Sulfamethoxazole	Rifampin <sup>e</sup>	Linezolid	Tetracycline	Nitrofurantoin <sup>f</sup>	
<i>Enterococcus</i> spp. (152)		93				100	n.d.	73	69					n.d.	89
<i>Staphylococcus aureus</i> (306)			57	100	100				50	74	99	100	100	99	99
<i>Staphylococcus epidermidis</i> (77)			30	100	100				47	68	58	97	100	92	100
<i>Staphylococcus lugdunensis</i> (54)			94	100	100				96	94	100	100	100	94	98
<i>Streptococcus pyogenes</i> (n.a.) <sup>g</sup> (Group A <i>Streptococcus</i> )	100														
<i>Streptococcus agalactiae</i> (162) <sup>h</sup> (Group B <i>Streptococcus</i> )	100			100						60					

<sup>a</sup> Isolates tested and reported are from all sources (surveillance isolates excluded), Jan to Dec, 2020 with the exception of *Staphylococcus epidermidis* and *Staphylococcus lugdunensis* (collected from Jan 2019 to Dec 2020); data compiled according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) in their document M39-A4 (2014).

<sup>b</sup> Oxacillin accurately predicts the activity of all semi-synthetic penicillins, including cloxacillin, beta-lactam/beta-lactamase inhibitor combinations, cephalosporins, and carbapenems for *Staphylococcus aureus* and coagulase-negative staphylococci.

<sup>c</sup> Susceptibility to high-level gentamicin or high-level streptomycin indicates that these agents can be used in combination with a cell wall active agent (e.g., ampicillin or vancomycin) for synergy. Gentamicin and streptomycin should never be used alone as treatment for *Enterococcus* spp.

<sup>d</sup> Erythromycin activity predicts the activity of azithromycin and clarithromycin for staphylococci and streptococci.

<sup>e</sup> Rifampin should NOT be used alone as treatment for infection.

<sup>f</sup> Nitrofurantoin is indicated for acute cystitis only.

<sup>g</sup> n.a. = not applicable – Susceptibility testing of *Streptococcus pyogenes* is not routinely performed as 100% are susceptible to penicillin. If treating infection in a penicillin allergic patient, contact the lab for testing of second line agents.

<sup>h</sup> *Streptococcus agalactiae* isolates were obtained from vaginal/rectal swabs submitted for Group B *Streptococcus* detection to the Health Sciences Centre, St. Boniface Hospital, and Westman Laboratory in 2012.

**Table 3. In vitro activity of selected anti-infective agents tested against *Streptococcus pneumoniae*<sup>a</sup>**

Infection Type (number tested)	Percent Susceptible							
	Penicillin (oral)	Penicillin (intravenous)	Ceftriaxone	Vancomycin	Levofloxacin	Clarithromycin	Doxycycline	Trimethoprim-Sulfamethoxazole
<input type="checkbox"/> = Not tested, not routinely reported, or not recommended								
Systemic Isolates (Blood + CSF) <sup>b</sup>								
Meningitis (180)		83	96	100				86
Non-Meningitis infection (180)	83	98	99	100	99	68	92	86
Respiratory Isolates <sup>c</sup>								
Non-Meningitis infection (40)	78	95	98	100	100	68	83	80

<sup>a</sup> For *Streptococcus pneumoniae*, different susceptibility breakpoints for penicillin and ceftriaxone exist depending on whether meningitis or a non-meningitis infection is being treated (CLSI, M100, 30<sup>th</sup> edition). For penicillin, when treating a non-meningitis infection different breakpoints exist for oral and intravenous dosing. For non-meningitis infections, susceptibility to oral penicillin predicts susceptibility to amoxicillin. Oral agents are not appropriate for the treatment of bacterial meningitis.

<sup>b</sup> Systemic isolates were obtained from patients across Manitoba as part of the SAVE Study between January and December, 2017. CSF = cerebrospinal fluid.

<sup>c</sup> Respiratory isolates were obtained from patients at the Health Sciences Centre (HSC) and St. Boniface Hospital (SBH) between January and December, 2018.

**Table 4. In vitro activity of selected anti-infective agents tested against Methicillin-Susceptible and Methicillin-Resistant *Staphylococcus aureus* isolates<sup>a</sup>**

Organism (number tested)	Percent Susceptible							
	Oxacillin <sup>b</sup>	Vancomycin	Trimethoprim-Sulfamethoxazole	Erythromycin	Clindamycin	Tetracycline	Linezolid	Deplomycin
<input type="checkbox"/> = Not tested, not routinely reported, or not recommended								
Methicillin-Susceptible <i>Staphylococcus aureus</i> (174)	100		100	66	70	99		
Methicillin-Resistant <i>Staphylococcus aureus</i> (137)	0	100	98	29	78	99	100	100

<sup>a</sup> Isolates tested and reported are from all sources (surveillance isolates excluded), Jan to Dec, 2020; data compiled according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) in their document M39-A4 (2014).

<sup>b</sup> Oxacillin accurately predicts the activity of all semi-synthetic penicillins, including cloxacillin, beta-lactam/beta-lactamase inhibitor combinations, cephalosporins, and carbapenems for *Staphylococcus aureus*.

**Table 5. In vitro activity of selected anti-infective agents tested against anaerobic isolates collected from hospitals in Winnipeg<sup>a</sup>**

Organism (number tested)	Percent Susceptible						
	Penicillin	Amoxicillin-Clavulanate	Piperacillin-Tazobactam	Cefoxitin	Clindamycin	Meropenem	Metronidazole
<input type="checkbox"/> = Not tested, not routinely reported, or not recommended							
<i>Bacteroides</i> spp. (256)		91	n.d.	83	48	95	99
<i>Bacteroides fragilis</i> (74)		94	97	91	57	96	99
<i>Bacteroides ovatus</i> (37)		80	n.d.	64	51	89	97
<i>Bacteroides thetaotaomicron</i> (37)		97	n.d.	56	24	100	100
<i>Bacteroides fragilis</i> group (74)		88	n.d.	92	45	95	100

<sup>a</sup> Isolates were obtained from WRHA hospitals between Jan 2015 and July 2016; data compiled according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) in their document M39-A4 (2014).

n.d. = no data – absence of data for certain drug-organism combinations reflects limitations of the testing method currently used by Shared Health Clinical Microbiology laboratories.

**Table 6. In vitro activity of selected anti-fungal agents tested against *Candida* species collected from hospitals in Winnipeg<sup>a</sup>**

Organism (number tested)	Percent Susceptible		
	Fluconazole <sup>b</sup>	Voriconazole	Miconazole
<i>Candida albicans</i> (33)	100	100	100
<i>Candida glabrata</i> (34)	91	n.d.	97

<sup>a</sup> Data obtained by testing a random sample of *C. albicans* and *C. glabrata* isolates from Health Sciences Centre and St. Boniface Hospital, collected between Jan 2017 and Dec 2018. Susceptibility interpretations are based on updated CLSI breakpoints (M60, 1<sup>st</sup> Edition). Isolates tested and reported are from blood only.

<sup>b</sup> For fluconazole, there is only a susceptible-dose dependent (SDD) breakpoint for *C. glabrata*. The percentage of *C. glabrata* isolates that tested SDD to fluconazole was 91%. Susceptibility of SDD isolates to fluconazole is dependent on achieving the maximum blood level possible (i.e., should use the maximum dosage regimen). Consultation with infectious diseases is recommended for further guidance.

n.d. = breakpoints have not been defined for voriconazole versus *C. glabrata*.

**Table 7. Adult oral antimicrobial dosage guidelines**

Antibiotic	Usual Dosages	Cost (\$) per day <sup>a</sup>
<b>ANTIBACTERIAL AGENTS</b>		
<i>Penicillins</i>		
amoxicillin	500 mg tid	1.10
amoxicillin-clavulanate	500 mg tid or 875 mg bid	2.75–3.00
cloxacillin	500 mg qid	1.50
penicillin V	300 mg qid	0.30
<i>Cephalosporins</i>		
cephalexin	500 mg qid	1.80
<i>Macrolides</i>		
azithromycin	250–500 mg daily	1.25–2.50
clarithromycin	250–500 mg bid	2.25–3.25
<i>Fluoroquinolones</i>		
ciprofloxacin	250–750 mg bid	1.40–2.50
levofloxacin	500–750 mg daily	3.50–6.50
moxifloxacin	400 mg daily	1.50
<i>Others</i>		
clindamycin	450–600 mg tid	1.50–3.00
cotrimoxazole (TMP-SMX)	1 DS (double strength) tab bid	0.25
doxycycline	100 mg bid	1.30
nitrofurantoin (Macrobid <sup>®</sup> )	100 mg bid	1.50
metronidazole	500 mg tid	0.35
<b>ANTIFUNGAL AGENTS</b>		
fluconazole	100–400 mg daily	5.55–22.20
itraconazole	200–400 mg daily	8.00–16.00
<b>ANTIVIRAL AGENTS</b>		
acyclovir	200–800 mg 5x/day	5.00–16.00
valacyclovir	1 g tid	5.25

<sup>a</sup> Approximate cost per inpatient day excluding dispensing costs as of February 2017 based on the Manitoba Drug Interchangeability Formulary and Manufacturer's List Prices. Prices have been rounded.